WO2017014545A1 - Composition pharmaceutique pour soigner la maladie de parkinson et inhiber les effets secondaires de la lévodopa, contenant une hormone de concentration de la mélanine en tant que principe actif - Google Patents
Composition pharmaceutique pour soigner la maladie de parkinson et inhiber les effets secondaires de la lévodopa, contenant une hormone de concentration de la mélanine en tant que principe actif Download PDFInfo
- Publication number
- WO2017014545A1 WO2017014545A1 PCT/KR2016/007884 KR2016007884W WO2017014545A1 WO 2017014545 A1 WO2017014545 A1 WO 2017014545A1 KR 2016007884 W KR2016007884 W KR 2016007884W WO 2017014545 A1 WO2017014545 A1 WO 2017014545A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mch
- levodopa
- disease
- parkinson
- dopamine
- Prior art date
Links
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 title claims abstract description 123
- 101800002739 Melanin-concentrating hormone Proteins 0.000 title claims abstract description 122
- 102000047659 melanin-concentrating hormone Human genes 0.000 title claims abstract description 122
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims abstract description 66
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 62
- 229960004502 levodopa Drugs 0.000 title claims abstract description 60
- 230000000694 effects Effects 0.000 title claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000004480 active ingredient Substances 0.000 title claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 230000036541 health Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 74
- 238000011282 treatment Methods 0.000 claims description 50
- 229940088597 hormone Drugs 0.000 claims description 38
- 239000005556 hormone Substances 0.000 claims description 38
- 230000002776 aggregation Effects 0.000 claims description 36
- 238000004220 aggregation Methods 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 208000016285 Movement disease Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 abstract description 90
- 208000012661 Dyskinesia Diseases 0.000 abstract description 11
- 230000003291 dopaminomimetic effect Effects 0.000 abstract description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 162
- 229960003638 dopamine Drugs 0.000 description 81
- 230000014509 gene expression Effects 0.000 description 35
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 33
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 33
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 32
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 30
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 210000004556 brain Anatomy 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 238000010586 diagram Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 18
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 18
- 210000001259 mesencephalon Anatomy 0.000 description 17
- 102200036626 rs104893877 Human genes 0.000 description 17
- 238000011830 transgenic mouse model Methods 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 241000699660 Mus musculus Species 0.000 description 15
- 230000026731 phosphorylation Effects 0.000 description 15
- 238000006366 phosphorylation reaction Methods 0.000 description 15
- 230000001681 protective effect Effects 0.000 description 15
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 14
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 102000038030 PI3Ks Human genes 0.000 description 13
- 108091007960 PI3Ks Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 108091008611 Protein Kinase B Proteins 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 10
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 206010029260 Neuroblastoma Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000001577 neostriatum Anatomy 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000003125 immunofluorescent labeling Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 230000000324 neuroprotective effect Effects 0.000 description 8
- 230000007730 Akt signaling Effects 0.000 description 7
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 102000019355 Synuclein Human genes 0.000 description 7
- 108050006783 Synuclein Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 210000003523 substantia nigra Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 102100026882 Alpha-synuclein Human genes 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108050009621 Synapsin Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000007659 motor function Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 4
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 108090001076 Synaptophysin Proteins 0.000 description 4
- 102000004874 Synaptophysin Human genes 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 4
- 108090000185 alpha-Synuclein Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004227 basal ganglia Anatomy 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- -1 pH adjusters Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101150086096 Eif2ak3 gene Proteins 0.000 description 3
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 102000001435 Synapsin Human genes 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 229960004405 aprotinin Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000010825 rotarod performance test Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 3
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 3
- 229940048086 sodium pyrophosphate Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004515 ventral tegmental area Anatomy 0.000 description 3
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 2
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001573498 Compacta Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000024453 abnormal involuntary movement Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 102000004963 gamma-Synuclein Human genes 0.000 description 2
- 108090001121 gamma-Synuclein Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 229940048084 pyrophosphate Drugs 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- QAXBVGVYDCAVLV-UHFFFAOYSA-N tiletamine Chemical compound C=1C=CSC=1C1(NCC)CCCCC1=O QAXBVGVYDCAVLV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 101100323155 Dictyostelium discoideum snfA gene Proteins 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101150106280 Mchr1 gene Proteins 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- GDSCFOSHSOWNDL-UHFFFAOYSA-N Zolasepam Chemical compound N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F GDSCFOSHSOWNDL-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003295 arcuate nucleus Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000003799 beta-Synuclein Human genes 0.000 description 1
- 108090000182 beta-Synuclein Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- VXYRWKSIAWIQMG-UHFFFAOYSA-K manganese(2+) N-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate triphenylstannyl acetate Chemical compound [Mn++].[S-]C(=S)NCCNC([S-])=S.CC(=O)O[Sn](c1ccccc1)(c1ccccc1)c1ccccc1 VXYRWKSIAWIQMG-UHFFFAOYSA-K 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004523 tiletamine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960001366 zolazepam Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
Definitions
- the present invention relates to a pharmaceutical composition for treating Parkinson's disease and inhibiting levodopa side effects and a health functional food comprising melanin concentrating hormone as an active ingredient.
- Parkinson's disease is characterized by neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc), which gradually leads to depletion of dopamine in the striatum. Parkinson's disease breaks down the balance of the basal ganglia and impairs the function of motor neurons, causing rigidity, tremor, and ainesia. One to five percent of people over 50 are the second most common neurodegenerative diseases.
- Parkinson's disease The ultimate cause of Parkinson's disease is unknown, but several symptoms appear to be due to a deficiency of dopamine, a neurotransmitter in the brain made from nerve cells in the substantia nigra area of the normal brain. .
- Dopamine produced by neurons distributed in the black matter of the brain is linked to the basal ganglia of the brain, including the corpus striatum.
- the basal ganglia are intricately linked to the motor cortex and many other areas of the brain, making it an important part of the body's movements, allowing them to perform smooth, harmonious and accurate movements.
- Dopamine deficiency which is free from the end of basal ganglia dopaminergic nerves caused by such dopaminergic nerve damage, is a major cause of motility disorders in Parkinson's disease.
- Parkinson's disease namely, the destruction of the neural cells of the black matter, but active research is being conducted to find out.
- Infection theory such as viral encephalitis, immune theory that immune mechanisms are involved, genetic theory that innately inherits its substrate, theory that free radicals destroy nerve cells, poisoning theory of neurotoxic substances, and dopamine production and metabolism
- Infection theory such as viral encephalitis, immune theory that immune mechanisms are involved, genetic theory that innately inherits its substrate, theory that free radicals destroy nerve cells, poisoning theory of neurotoxic substances, and dopamine production and metabolism
- the neurotoxin 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine, MPTP) are mainly used (Nat Rev Neurosci, 2001, 2 (5), 325-334). 6-OHDA is absorbed by the dopamine transporter (DAT) and produces free radicals. MPTP reduces dopamine neurons in humans and nonhuman primates, causes astrocytes and activates microglia in cerebrospinal densities rather than specifically targeting dopaminergic neurons associated with Parkinson's disease (Nat Med, 1999, 5). (12), 1403-1409), causing typical biochemical or pathological symptoms of Parkinson's disease (Neurosci, 2000, 16 (2), 135-142).
- L-dopa preparations As drugs for the treatment of Parkinson's disease, L-dopa preparations, dopamine receptor agonists, anticholinergic drugs, eldefril and the like are known.
- the use of the dopamine precursor, L-dopa (levodopa), is an absolute criterion for treating Parkinson's disease, as motor neurons function dramatically in the early stages of Parkinson's disease.
- levodopa causes side effects such as hallucination, insomnia, nausea and dyskinesia.
- levodopa-induced dyskinesia LID is the most serious side effect in patients with Parkinson's disease who are chronically using levodopa.
- Anticholinergic drugs may show autonomic nervous system abnormalities or mental function abnormalities, and thus they are limited to continuous administration to older patients.
- surgical treatment such as high frequency nerve stimulation, that is, high frequency destruction or deep brain stimulation, is also performed, but there is a problem that requires invasive surgery and consumes a lot of money.
- MCH melanin-concentrating hormone
- One object of the present invention to provide a pharmaceutical composition for the treatment or prevention of Parkinson's disease comprising melanin concentrating hormone (melanin concentrating hormone) as an active ingredient.
- Another object of the present invention to provide a health functional food for improving or preventing Parkinson's disease comprising melanin aggregation hormone as an active ingredient.
- Another object of the present invention is to provide a pharmaceutical composition for treating or preventing Parkinson's disease, including MCH and levodopa.
- Another object of the present invention to provide a pharmaceutical composition for inhibiting levodopa side effects, including melanin aggregation hormone and levodopa.
- MCH is applied to dopamine neurons.
- the present invention was completed by confirming that it has a protective effect and alleviates a motor disorder caused by levodopa.
- composition comprising the melanin aggregation hormone of the present invention as an active ingredient restores the loss of dopamine neurons, and thus has an excellent effect on the treatment and prevention of Parkinson's disease, and improves dyskinesia caused by levodopa, a treatment for Parkinson's disease. There is.
- FIG. 1 is a diagram showing the change in the number of dopamine neurons after the treatment of MCH, MCH + anti-MCH to the brain brain dopamine neurons.
- Figure 2 is a diagram showing the change in the number of dopamine neurons through the immunofluorescence staining of Tuj1 and MAP2 by treating MCH, MCH + anti-MCH to the brain brain dopamine neurons.
- Figure 3 is a diagram showing the qRT-PCR results of the dopamine neuron marker genes of MAP2, DAT, TH, AADC after the treatment of MCH in the brain brain dopamine neurons.
- Figure 4 shows the number of dopamine neurons different in the treatment of MCH by concentration in the midbrain dopamine neurons.
- 5 is a diagram showing the expression level of the marker gene.
- Figure 6 is a diagram showing the change in the number of dopamine neurons after MCH treatment to 6-hydroxy dopamine or MPP + -treated midbrain dopamine neurons.
- Figure 7 shows the number of dopamine neurons through immunofluorescence staining for TH, MAP2 after MCH treatment of 6-hydroxydopamine or MPP + -treated midbrain dopamine neurons and untreated midbrain dopamine neurons.
- Figure 8 is a diagram showing the expression level of the gene through qRT-PCR for TH, DAT and synapsin after MCH treatment in 6-hydroxy dopamine or MPP + -treated midbrain dopamine neurons.
- Figure 9 is a diagram analyzing the overall gene expression after the treatment of MCH in the brain brain dopamine neurons.
- 10 is a diagram showing the expression of pCREB, pGSK-3 ⁇ , pAkt, and pERK proteins through Western blot after treatment with MCH in mesenchymal dopamine neurons.
- 11 is a diagram showing the results of measuring the phosphorylation level of pCREB, pGSK-3 ⁇ , pAkt and pERK using phosphate-specific antibodies after MCH treatment in midbrain dopamine neurons.
- FIG. 12 is a diagram showing that neuroprotective effect is suppressed through immunofluorescence staining of Tuj1 and MAP2 after treatment with PI3K and PKA signaling specific inhibitors to MCH-treated midbrain dopamine neurons.
- 13 is a diagram showing the results of FIG. 12 numerically.
- Figure 14 after treatment with MCH in MPP + -induced midbrain dopamine neuron killing environment, after treatment with PI3K and PKA signaling inhibitors, the neuronal protective effect against neuronal cell death through immunofluorescence staining of Tuj1 and MAP2 Is a diagram showing suppression. 15 is a diagram showing the results of FIG. 14 numerically.
- FIG. 16 is a diagram showing that apoptosis is inhibited by MCH treatment of 0, 50 and 100 nM MCH in 6-OHDA induced human neuroblastoma SY-SY5Y cells.
- FIG. 17 is a diagram illustrating phosphorylation levels of Ikb- ⁇ and p38 through Western blot after treatment of 6-OHDA-induced human neuroblastoma SY-SY5Y cells with MCH.
- 18 is a diagram showing the results of FIG. 17 numerically.
- 19 is a diagram showing the change of TH-positive neurons in the black matter after MCH injection into the MPTP-treated mice.
- 20 is a diagram showing the density change of TH-positive fibers in the striatum after MCH injection into the MPTP-treated mice.
- 21 is a diagram showing that the motor function is improved after injecting MCH to the MPTP-treated mice.
- FIG. 22 is a diagram showing the expression of TH and synaptophysin proteins in black matter through Western blot after injection of MCH into mice treated with MPTP.
- FIG. 23 is a diagram showing the results of FIG. 22 in TH and synaptophysin / ⁇ -actin (%).
- FIG. 24 and 25 show the results of measuring the phosphorylation level of pAkt and pCREB through Western blot after injection of MCH into MPTP treated mice.
- Figure 26 is a diagram showing the result of measuring the motor function through the rotarod test at 2 and 4 weeks after MCH injection into A53T alpha-synuclein transgenic mice.
- FIG. 27 shows the results of measuring phosphorylation levels of pGKS-3 ⁇ and pAMPK through Western blot after MCH injection into A53T alpha-synuclein transgenic mice.
- FIG. 28 is a diagram quantifying the results of FIG. 27.
- FIG. 29 shows protein expression of synuclein, BDNF after MCH injection into A53T alpha-synuclein transgenic mice.
- FIG. 30 is a diagram showing the results of FIG. 29 using synuclein and BDNF / ⁇ -actin.
- FIG. 31 shows abnormal involuntary motility (AIM) at 1, 4 and 7 days after injection of levodopa and MCH at concentrations of 0.1 ⁇ g, 0.5 ⁇ g and 2.5 ⁇ g in 6-hydroxydopamine-induced Parkinson's disease model animals. The figure which shows the result of measuring.
- AIM abnormal involuntary motility
- the present invention provides a pharmaceutical composition for the treatment or prevention of Parkinson's disease comprising melanin concentrating hormone (melanin concentrating hormone) as an active ingredient.
- 'melanin aggregation hormone' used in the present invention is a kind of neuropeptide, which is distributed in the central nervous system, and is known to be involved in dietary control and weight control of foods. It is known to have a function of softening and inhibiting melanin production. However, melanin aggregation hormone has a neuroprotective effect in the dopamine neurons, through which it has been identified for the first time through the Parkinson's disease treatment effect and dyskinesia induced effect from levodopa through the present invention.
- the amino acid sequence of the melanin aggregation hormone and the nucleotide sequence information of the gene encoding the same are known to the NCBI (Genbank: NP_002665, NM_002674).
- the term 'Parkinson' disease used in the present invention is caused by the progressive loss of dopamine neurons distributed in the substantia nigra of the brain, chronic progressive degenerative of the nervous system, which is characterized by stability, stiffness, locomotor movement and postural instability. Means disease.
- the term 'prevention' refers to any action of inhibiting or delaying Parkinson's disease by administration of a composition containing the melanin aggregation hormone as an active ingredient.
- treatment refers to any action in which the symptoms of the disease are improved or advantageously changed by administration of the composition containing the melanin aggregation hormone as an active ingredient.
- the treatment of Parkinson's disease may be due to neuronal cell protection, motor function or neuronal cell number increase.
- the neuron is a dopamine neuron, which may mean a neuron whose main neurotransmitter is dopamine, ventral tegmental area (VTA), substantia nigra pars compacta, hypothalamus arch of the middle brain It may be located in the nucleus (arcuate nucleus of the hypothalamus) or striatum.
- VTA ventral tegmental area
- substantia nigra pars compacta hypothalamus arch of the middle brain It may be located in the nucleus (arcuate nucleus of the hypothalamus) or striatum.
- the melanin aggregation hormone of the present invention is treated to dopamine neurons, and then immunofluorescence staining is performed on neuron-related genes such as Tuj1 (class III beta-tubulin) and MAP2 (microtubule associated protein 2). It was confirmed that the number of dopamine neurons is increased, the number of dopamine neurons is effectively suppressed by the treatment of anti-melanin aggregation hormone (Fig. 1 to 2).
- Tuj1 class III beta-tubulin
- MAP2 microtubule associated protein 2
- melanin aggregation hormone is MPP + or 6-OHDA It was confirmed to restore the death of neurons induced by (Figs. 6 to 8).
- composition of the present invention may be to suppress the side effects of levodopa which is a therapeutic agent for Parkinson's disease.
- levodopa is the most widely used drug in the treatment of Parkinson's disease, and it is known that administered levodopa freely crosses the blood brain barrier to artificially promote dopamine secretion.
- side effects of levodopa include hallucination (hallucination), insomnia, nausea and dyskinesia.
- exercise disorders include movement impairment, for example, slow and non-cooperative involuntary movements, shaking (the appearance of shaking, stiffness and gait disturbances. Patients treated with levodopa often have reduced Parkinson's disease symptoms, but they experience increasingly difficult to keep standing or even sitting.
- composition of the present invention is tyrosine hydroxylase (TH), dopamine transporter (DAT), aromatic l-amino acid decarboxylase (AADC), MAP2 (microtuble associated protein 2) and increase the expression of one or more genes selected from the group consisting of synapsin, brain-derived neurotrophic factor protein, synaptophysin or tyrosine hydroxylase (tyrosine) It may be to increase the expression of hydroxylase (TH) protein or to reduce the expression of synuclin (synucelin) protein.
- the MAP2 belongs to a microtubule associated protein and is involved in microtubule assembly. It is known that microtubules are primarily involved in microtubule assembly by combining with other microtubules and intermediate fibers.
- composition of the present invention may be to increase the activity of pCREB, pGSK, pAkt or pAMPK, to inhibit the activity of Ikb ⁇ or p38, or to increase the activity of PI3K or PKA.
- Akt signaling-related genes was increased through analysis of global gene expression in dopamine neurons treated with melanin aggregation hormone, and pCREB, pGSK and pAkt through Western blots for pCREB, pGSK and pAkt. It was confirmed that the phosphorylation of the Akt signaling-related protein including the (Fig. 9 to Fig. 11).
- A53T alpha-synuclein transgenic mouse used in the present invention is a transformant in which the alanine, which is the 53rd amino acid, is transformed into threonine, and the mutant aggregates alpha-synuclein, a dopamine neurodegenerative protein, Causes degeneration of dopamine neurons.
- the neuronal protective effect of melanin aggregation hormone was confirmed using A53T alpha-synuclein transgenic mice.
- the alpha-synuclein is part of a large protein family including beta- and gamma-synuclein and synoretin. Dual alpha-synuclein is known to be expressed in the normal state associated with synapses and play a role in neuroplasticity, learning and memory. Alpha-synuclein can be an important protein in Parkinson's and related diseases because it can induce neuronal death and neuroinflammatory and can be a mediator of aggregate spreading in the brain (Proc Natl Acad Sci USA , 2009; 106: 13010-5; J Biol Chem, 2010a; 285: 9262-72).
- the A53T alpha-synuclein transgenic mice injected with melanin coagulation hormone was longer in the rod than the non-injecting group, the melanin coagulation hormone through the exercise improvement effect It can be seen that (Fig. 26).
- composition of the present invention may be administered in a pharmaceutically effective amount.
- the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type and severity, age, sex, disease of the individual. It can be determined according to the type, activity of the drug, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including the drug used concurrently and other factors well known in the medical field.
- the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations.
- compositions of the present invention depend on the condition and weight of the patient, the extent of the disease, the form of the drug, the route and duration of administration, and the suitable total daily dosage can be determined by the practitioner within the scope of good medical judgment, It may generally be in an amount of 0.001 to 1000 mg / kg.
- the composition is not particularly limited as long as it is an individual for the purpose of preventing or treating Parkinson's disease, and any individual may be applied.
- any individual such as monkeys, dogs, cats, rabbits, marmots, rats, mice, cows, sheep, pigs, goats, and the like, and to humans, and the mode of administration is conventional in the art. If not included.
- transdermal administration through topical application may be used, but is not limited thereto.
- compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.
- the pharmaceutical composition for treating or preventing Parkinson's disease of the present invention may include a pharmaceutically acceptable carrier, excipient or diluent in addition to the active ingredient described above.
- the carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- compositions of the present invention may be used in the form of oral dosage forms, external preparations, suppositories, or sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods.
- it may be prepared by using diluents or excipients such as fillers, weighting agents, binders, wetting agents, disintegrating agents, and surfactants which are commonly used.
- Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like.
- Such solid preparations may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like.
- excipients such as starch, calcium carbonate, sucrose, lactose, gelatin and the like.
- lubricants such as magnesium stearate, talc can also be used.
- It may be prepared by adding various excipients such as humectants, sweeteners, fragrances, preservatives and the like in addition to liquid oral liquids or liquid paraffin for oral use.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations and suppositories.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.
- base of the suppository utopsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- the route of administration of the pharmaceutical composition of the present invention may be one selected from the group consisting of oral, subcutaneous, intraperitoneal, pulmonary, intranasal, intramuscular, intravenous and arterial.
- the melanin aggregation hormone solution was injected into the nasal cavity of the mouse injected with MPTP or A53T alpha-synuclein transgenic mice after dissolving melanin aggregation hormone in the saline solution.
- the dosage depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the time of day, and may be appropriately selected by those skilled in the art.
- the present invention provides a health functional food for improving or preventing Parkinson's disease comprising melanin aggregation hormone as an active ingredient.
- the health functional food of the present invention may be to suppress the side effect of levodopa Parkinson's disease improver. Specifically, it may be to suppress the movement disorder caused by the side effects of levodopa, a Parkinson's disease improving agent.
- Parkinson's disease The definition of the melanin aggregation hormone, Parkinson's disease is as described above.
- 'health functional food' used in the present invention means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No.6775 of the Health Functional Food Act. This means that it is ingested for the purpose of obtaining useful effects on health use such as nutrient control or physiological action on the structure and function of the human body.
- the health functional food includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof, Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like.
- dietary supplement may be in the form of any one of meat, sausage, bread, chocolate, candy, confectionary, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcoholic beverage and vitamin complex. have.
- the health functional food may further include food additives, and the suitability as a 'food additive' is related to the relevant items according to the General Regulations of the Food Additives Code and General Test Act, etc., unless otherwise specified. Judging by the standards and standards.
- the chemical additives such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as navy dye, licorice extract, crystalline cellulose, guar gum, and sodium L-glutamate Mixed preparations, such as a preparation, an alkali addition agent, a preservative preparation, and a tar pigment preparation, are mentioned.
- composition of the present invention provides a pharmaceutical composition for treating or preventing Parkinson's disease, including melanin aggregation hormone and levodopa.
- composition of the present invention may be that levodopa side effects are suppressed compared to the levodopa alone administration group. Specifically, it may be that the movement disorder caused by levodopa compared to the levodopa alone administration group is suppressed.
- the composition of the present invention exhibits a dopamine neuron protective effect, it may be administered alone to treat Parkinson's disease, or by administering the pharmaceutical composition of the present invention and levodopa in parallel, the Parkinson's disease may be treated.
- the pharmaceutical composition of the present invention and levodopa a Parkinson's disease therapeutic agent
- the activity of the conventional Parkinson's disease therapeutic agent and the therapeutic activity represented by the pharmaceutical composition of the present invention can be duplicated to more effectively treat Parkinson's disease.
- the side effects of levodopa which is a side effect of movement disorders also have an effect.
- the combination dosage agent which can be used at this time is not specifically limited as long as it shows the therapeutic activity of Parkinson's disease as well as levodopa.
- dyskinesiasis in a group administered with levodopa and melanin aggregation hormone in combination with levodopa alone in a Parkinson's disease model animal induced with 6-hydroxydopamine (6-OHDA). was less induced (FIG. 31).
- the present invention also provides a pharmaceutical composition for inhibiting levodopa side effects, including melanin aggregation hormone and levodopa.
- composition of the present invention may be that levodopa side effects are suppressed compared to the levodopa alone administration group. Specifically, it may be that the movement disorder caused by levodopa compared to the levodopa alone administration group is suppressed.
- composition of the present invention suppresses the side effects of levodopa
- levodopa side effects can be suppressed.
- the pharmaceutical composition of the present invention and levodopa which is a Parkinson's disease therapeutic agent
- the activity of the conventional Parkinson's disease therapeutic agent and the therapeutic activity represented by the pharmaceutical composition of the present invention may overlap, thereby more effectively treating Parkinson's disease.
- Exercise disorders, a side effect of levodopa also have an inhibitory effect.
- Example 1 in primary dopamine neurons and human neuroblastoma cells MCH Functional Roles and Neuronal Protection Mechanisms
- midbrain containing SNC and VTA was easily cut by treatment with papain at 37 ° C. for 30 minutes (5 U / ml; Worthington Biochemicals). The cut tissue was made into single cells through chewing using a small pipette tip. Cells were then centrifuged at 250 xg for 5 minutes and 5% fetal bovine serum, 1x B27 (Invitrogen), 1x GlutaMAX (Invitrogen), 0.4% D-glucose (Sigma-Aldrich), 10 U / ml penicillin (Invitrogen) , And 10 ⁇ g / ml streptomycin (invitrogen) were suspended in plating medium.
- the cells isolated from each midbrain were divided equally and dispensed onto 4 poly-D-lysine (Sigma) and laminin (BD Bioscience) precoated 12-mm-round coverslips, followed by carbon dioxide It was kept at 37 ° C. in an incubator humidified with. At 24 hours after dispensing, the medium was changed to serum-free medium supplemented with 5 uM cytosine ⁇ -D-arabinofuranoside ( ⁇ -D-arabinofuranoside, Sigma Aldrich). glia) was used to inhibit the proliferation. Three days after plating, the medium was treated with MCH or other drugs.
- Human neuroblastoma SH-SY5Y cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA), 100 unit / ml penicillin, and 100 ⁇ g / ml streptoceat at 37 ° C., 95% air, and 5% CO 2 atmosphere. DMEM (Dulbecco's modified Eagle's minimum essential medium, Invitrogen, Carlsbad, CA, USA with the addition of mycin (Gibco-BRL, Rockville, MD, USA) and additionally trypsin-EDTA (Gibco-BRL, Rockville, MD, USA) ).
- MTT Thiazolyl Blue Tetrazolium Bromide
- DMSO dimethyl sulfoxide
- Cells were fixed with PBS containing 4% paraformaldehyde and immunostaining was performed using the following primary antibodies according to standard protocols: Tuj1 (mouse monoclonal, Covance); TH (rabbit polyclonal, Pelfreez); Appropriate Molecular Probes Secondary antibodies linked with Alexa Fluor® stains were used. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (4,6-diamidino-2-phenylindole, DAPI, Invitrogen). Cells were imaged with Nikon Eclipse Ti, and images were processed and analyzed with Adobe Photoshop software. Immunoblotting was performed according to standard protocols.
- RNase H-mediated second-strand cDNA RNase H-treated cDNA
- the cRNA produced through in vitro transcription was combined with a biotin-coupled nucleotide analog during cDNA synthesis. Samples were prepared by placing 15 ⁇ g of biotin-bound cDNA into a 1 ⁇ hybridization cocktail according to the Affymetrix Hybridization Manual.
- GeneChip arrays (GeneChip array, mouse genome 430A 2.0 arrays) were hybridized in a gene chip hybridization oven at 45 °C for 16 hours at 60 RPM. Washing was performed in GeneChip Fluidics Station 450 with buffer provided by Affymetrix GeneChip Hybridization, Wash, and Stain Kit. Analysis results were scanned with GeneChip Scanner 3000, and images were extracted and analyzed with GeneChip Operating Software v1.4. For statistical analysis, CEL files were processed using GeneSpring 7.0 and normalized using robust multi-array analysis.
- Cells were 50 mM tris-base (pH 7.5), 150 mM sodium chloride, 2 mM EDTA, 1% glycerol, 10 mM sodium fluoride (NAF), 10 mM sodium-pyrophosphate, 1% NP- Homogenized in lysis buffer containing 40 and protease inhibitor (0.1 mM phenylmethylsulfonylfluoride, 5 ⁇ g / ml aprotinin, and 5 ⁇ g / ml leupeptin).
- protease inhibitor 0.1 mM phenylmethylsulfonylfluoride, 5 ⁇ g / ml aprotinin, and 5 ⁇ g / ml leupeptin.
- qRT-PCR was performed using the dopamine neuron medium treated with MCH.
- TH tyrosine hydroxylase
- DAT dopamine transporter
- AADC aromatic l-amino acid decarboxylase
- fine particles were treated by the MCH treatment. It was confirmed that the expression of dopamine (dopamine, DA) marker gene including microtubule associated protein 2 (MAP2) increased (FIG. 3).
- MCH plays an important role in the maintenance and survival of midbrain dopamine neurons.
- MCH changes the overall gene expression, among which the expression of Akt signaling-related genes increased after the treatment of MCH (Fig. 9).
- Akt signaling is involved in the neuronal cell protection mechanism of MCH, and CREB, Akt and GSK-3 ⁇ are involved in Akt signaling, but not ERK.
- MPP + induced dopamine neurons were treated with MCH together with PI3K (LY294002) and PKA (H89) signaling specific inhibitors.
- PI3K LY294002
- PKA H89
- Akt and CREB are involved in the protective effect of dopamine neurons induced by MCH using PI3K and PKA signaling inhibitors.
- MCH exhibited a strong protective effect in neurons by inhibiting the activation of Ikb- ⁇ or p38.
- the 12-week-old male C57BL / 6 mouse (Central Laboratories Animal Inc, Republic of Korea), weighing 23-25 g, was kept for 12 hours in light and 12 hours in dark, and free access to water and food. Room temperature was maintained at 23 ⁇ 1 ° C. All experiments were approved by Kyung Hee University Animal Protection Committee for Animal Welfare.
- MCH was injected by intranasal injection, a noninvasive method that bypasses the blood brain barrier to deliver drugs from the nasal cavity to the brain.
- intracerebroventricular injection is widely used for brain specific delivery of certain drugs, it is an invasive method and needs to anesthetize the experimental animal. Therefore, intranasal injection was chosen as the next best method for delivering MCH to the brain. Intranasal infusion was performed as described in De Rosa et al., 2005. MCH (Tocris biosciences, Bristol, UK) was injected intranasally into mice 2 hours after MPTP injection. Prior to injection, MCH was dissolved in saline solution (saline, 0.5 mg / 30 ⁇ L) and stored at 4 ° C.
- saline solution saline, 0.5 mg / 30 ⁇ L
- mice All mice were held in a standing position to hold their heads and necks intact, and 15 ⁇ l of MCH solution was slowly injected with a pipette for about 15 seconds into one nasal cavity. After 2 to 3 minutes, the same injection was repeated in the other nostril. Another group of mice received a salt solution (i.n.).
- Tissue sections were reacted with biotin-conjugated anti-rabbit IgG (Vector Laboratories Inc., Burlingame, CA, USA) for 1 hour at room temperature, and for 1 hour with ABC reagent (Vector Laboratories Inc., Burlingame, CA, USA).
- the reaction was carried out at room temperature and for 2 minutes in 1 M Tris-buffered saline (pH 7.5) containing 0.02% diaminobenzidine and 0.003% hydrogen peroxide.
- the tissue sections were fixed and dried on gelatin-coated slides, water was removed and the cover was covered. Photographs of striatum and black matter were taken using a brightfield microscope (BX51; Olympus, Tokyo, Japan). Three independent observers who did not know the expected results counted TH-positive neurons in the black matter. Counted cells were checked three times for validity of the data.
- Substantia nigra contains 50 mM tris-base (pH 7.5), 150 mM sodium chloride, 2 mM EDTA, 1% glycerol, 10 mM sodium fluoride (NAF), 10 mM sodium-pyrophosphate (Na-pyrophosphate). ), 1% NP-40 and a protease inhibitor (0.1 mM phenylmethylsulfonylfluoride, 5 ⁇ g / ml aprotinin, and 5 ⁇ g / ml leupeptin) Homogenized.
- phosphorylation levels of Akt and CREB were confirmed in black matter isolated from mice treated with MPTP.
- phosphorylation levels of Akt and CREB decreased in the black matter of MPTP-treated mice, but recovered in the black matter of MCH-infused or acupuncture mice (FIGS. 24 and 25). ).
- Heterozygous breeder of A53T alpha-synuclein (B6; C3-Tg-Prnp / SNCA * A53T / 83Vle / J) variant was purchased from Jackson Laboratories (Bar Harbor, ME, USA), and A53T transgenic and non-transformant Breeding was obtained to obtain litters.
- mice Genotyped mice were reared free of water and food in a temperature and humidity controlled room at 12 hour light / dark cycles.
- MCH Tocris biosciences, Bristol, UK
- salt solution 0.5 mg / 30 ⁇ L
- the control group CON
- mice were pre-trained for 2 minutes in accelerated road speed mode one hour before the experiment.
- the time on the road was up to 480 seconds at continuous load speed. Latency time was also analyzed.
- cells and black matter were treated with 50 mM tris-base (pH 7.5), 150 mM sodium chloride, 2 mM EDTA, 1% glycerol, 10 mM sodium fluoride (NAF), 10 mM sodium-pyrophosphate (Na dissolution including -pyrophosphate), 1% NP-40 and protease inhibitor (0.1 mM phenylmethylsulfonylfluoride, 5 ⁇ g / ml aprotinin, and 5 ⁇ g / ml leupeptin) Homogenized in solution.
- protease inhibitor 0.1 mM phenylmethylsulfonylfluoride, 5 ⁇ g / ml aprotinin, and 5 ⁇ g / ml leupeptin
- MCH phosphorylation of GSK3 ⁇ , phosphorylation of AMPK, brain-derived neurotrophic factor (BDNF) expression, and down-ampling of AMPK as targets of Akt in the black matter Expression of synuclein was confirmed as a stream target.
- MCH increased phosphorylation expression of GSK3- ⁇ and AMPK in black matter of A53T alpha-synuclein transgenic mice, increased expression of BDNF protein, and decreased expression of synuclein protein (FIGS. 27-30). ).
- mice Nine week old male C57BL / 6 mice (Central Lab. Animal Inc., Seoul, Republic of Korea) weighing 24-26 g each were used. All experiments were approved by the Kyung Hee University Animal Protection Committee for Animal Welfare and were strictly maintained according to the guidelines of the NIH and the Korean Medical Association. Stereotaxic surgery was performed to create unilateral 6-OHDA lesions in striata of mice.
- mice were treated with tiletamine + zolazepam (30 mg / kg; Zoletil 50, Virbac, France) and xylazine (10 mg / kg; Rompun, Bayer Korea, Republic of Korea ) Was anesthetized with physiological saline and fixed in a stereotactic frame with a mouse adapter (Stoelting Co., USA). 6-OHDA-HCl mixture (3.0 mg / ml; Sigma Aldrich, USA) was dissolved in 0.02% ascorbic acid-based saline.
- mice were injected with either saline solution or 6-OHDA in the right striatum, unilaterally according to the brain atlas of the mouse: +1.0 mm of AP, -2.1 mm of ML, -3.2 mm of DV; And +0.3 mm of AP, -2.3 mm of ML, -3.2 mm of DV (BJ and GP, 2008).
- Each flow rate is 0.5 ⁇ l / min.
- LID levodopa induced dyskinesia
- AIM axial AIM
- limb AIM repetitive and regular spasm or dystonia of the forelimbs
- AIM orolingual AIM
- dyskinesia was quantified on a 4-point scale that reflects frequency (0, none; 1, sometimes; 2, frequent; 3, interrupted by an external stimulus but continued; 4, external Continuous and serious without being interrupted by the stimulus).
- three subtypes of AIM values were integrated.
- AIM levels were evaluated after L-dopa injection.
- the group administered with L-dopa (20 mg / kg) induced more dyskinesia (p ⁇ 0.05) compared with the 6-OHDA group and the control group.
- the group injected with MCH (0.5 mg / kg) with L-dopa induced less dyskinesia than the group that received only L-dopa (p ⁇ 0.05) (FIG. 31).
- Sub-analysis of AIM levels showed that all subcategories of AIM levels also had this tendency.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une composition pharmaceutique et un aliment fonctionnel diététique pour soigner la maladie de Parkinson ou inhiber les effets secondaires de la lévodopa, contenant une hormone de concentration de la mélanine en tant que principe actif. La composition selon la présente invention, contenant une hormone de concentration de la mélanine en tant que principe actif, permet de récupérer les cellules nerveuses dopaminergiques perdues, ce qui lui permet de soigner et prévenir la maladie de Parkinson de manière performante, et a pour effet de soulager la dyskinésie induite par la lévodopa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0102459 | 2015-07-20 | ||
KR1020150102459A KR101749675B1 (ko) | 2015-07-20 | 2015-07-20 | 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017014545A1 true WO2017014545A1 (fr) | 2017-01-26 |
Family
ID=57834905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/007884 WO2017014545A1 (fr) | 2015-07-20 | 2016-07-20 | Composition pharmaceutique pour soigner la maladie de parkinson et inhiber les effets secondaires de la lévodopa, contenant une hormone de concentration de la mélanine en tant que principe actif |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101749675B1 (fr) |
WO (1) | WO2017014545A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102001338B1 (ko) | 2018-02-08 | 2019-07-17 | 동국대학교 경주캠퍼스 산학협력단 | 혼합 생약 추출물을 유효성분으로 함유하는 파킨슨병의 예방 또는 치료용 약학적 조성물 |
WO2025080080A1 (fr) * | 2023-10-10 | 2025-04-17 | 한양대학교 산학협력단 | Composition pharmaceutique pour prévenir ou traiter la maladie de parkinson, contenant un inhibiteur de pdk en tant que principe actif |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210076A (en) * | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
US20030031707A1 (en) * | 1997-04-08 | 2003-02-13 | Alan A. Rubin | Treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
KR20100088136A (ko) * | 2007-10-12 | 2010-08-06 | 노파르티스 아게 | 파킨슨병의 치료를 위한 대사성 글루타메이트 수용체 조절제 |
KR20150017763A (ko) * | 2012-06-11 | 2015-02-17 | 싸이코제닉스 아이엔씨. | 파킨슨병 치료와 관련된 운동 장애 부작용의 치료 |
-
2015
- 2015-07-20 KR KR1020150102459A patent/KR101749675B1/ko active Active
-
2016
- 2016-07-20 WO PCT/KR2016/007884 patent/WO2017014545A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210076A (en) * | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
US20030031707A1 (en) * | 1997-04-08 | 2003-02-13 | Alan A. Rubin | Treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
KR20100088136A (ko) * | 2007-10-12 | 2010-08-06 | 노파르티스 아게 | 파킨슨병의 치료를 위한 대사성 글루타메이트 수용체 조절제 |
KR20150017763A (ko) * | 2012-06-11 | 2015-02-17 | 싸이코제닉스 아이엔씨. | 파킨슨병 치료와 관련된 운동 장애 부작용의 치료 |
Non-Patent Citations (2)
Title |
---|
LEE: "A Novel Target for L-dopa Induced Dyskinesia in Parkinson's Disease: the Role of Melanin Concentrating Hormone", MASTER'S THESIS OF KYUNGHEE UNIVERSITY, February 2016 (2016-02-01) * |
THANVI ET AL.: "Levodopa-induced Dyskinesia in Parkinson's Disease: Clinical Features, Pathogenesis, Prevention and Treatment", POSTGRADUATE MEDICAL JOURNAL, vol. 83, 2007, pages 384 - 388, XP055348991 * |
Also Published As
Publication number | Publication date |
---|---|
KR101749675B1 (ko) | 2017-06-26 |
KR20170010947A (ko) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017078499A2 (fr) | Composition pour la prévention ou le traitement d'une maladie neuroinflammatoire, contenant un inhibiteur de la protéine tyrosine phosphatase | |
WO2014182051A1 (fr) | Composition comprenant un inhibiteur asm comme principe actif pour prévenir ou traiter des troubles neurologiques dégénératifs | |
WO2018097628A2 (fr) | Composition permettant de favoriser la différenciation de cellules souches neurales et de les protéger et procédé permettant d'induire une régénération neurale utilisant celle-ci | |
WO2019231220A1 (fr) | Utilisation d'un composé thiophène 2,3,5-substitué pour prévenir, atténuer ou traiter des cancers du sein | |
WO2009093864A2 (fr) | Composition pour prévenir ou traiter des maladies du cerveau | |
WO2017048072A1 (fr) | Composition de promotion de différenciation de myocytes contenant des acides aminés | |
WO2017014545A1 (fr) | Composition pharmaceutique pour soigner la maladie de parkinson et inhiber les effets secondaires de la lévodopa, contenant une hormone de concentration de la mélanine en tant que principe actif | |
WO2021015437A1 (fr) | Composition pour la prévention, le traitement ou l'atténuation d'une maladie infectieuse virale, contenant un inhibiteur de production d'oxygène actif et un complexe capteur d'oxygène actif utilisés comme principes actifs | |
WO2023177128A1 (fr) | Composition comprenant un inhibiteur alox5 pour la prévention ou le traitement de la sarcopénie | |
WO2020106048A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement d'une maladie neurodégénérative | |
WO2017043935A1 (fr) | Composition pour prévenir ou traiter des maladies liées à une faiblesse musculaire comprenant du sobrerol | |
WO2020040382A1 (fr) | Nouveau composé de magnésium-sérinate et son utilisation | |
WO2013022139A1 (fr) | Méthode de traitement de maladies provoquées par l'accumulation de bêta-amyloïdes dans le parenchyme cérébral par des dérivés thiazolidinediones à faible concentration | |
WO2021261631A1 (fr) | Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées | |
WO2019078381A1 (fr) | Composition pharmaceutique, composition alimentaire et additif alimentaire pour prévenir, soulager ou traiter la perte, la faiblesse et l'atrophie musculaires, contenant, à titre de principe actif, une bactérie enterococcus faecalis, le liquide de culture ou des cellules mortes de celle-ci | |
WO2021002664A1 (fr) | Composition pour la prévention, le soulagement ou le traitement d'un cancer | |
WO2022163971A1 (fr) | Composition pharmaceutique composite pour le traitement d'une maladie du cerveau, comprenant un inhibiteur de cholinestérase et un antioxydant | |
WO2021033995A1 (fr) | Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie | |
WO2015108372A1 (fr) | Composition pour la prévention ou le traitement de troubles neurologiques provoqués par une excitotoxicité ou un dysfonctionnement synaptique, contenant de l'osmotine, et méthode pour la prévention ou le traitement de troubles neurologiques en faisant appel à celle-ci | |
WO2023027540A1 (fr) | Composition pour la prévention, l'amélioration ou le traitement de maladies musculaires comprenant du ginsénoside rc | |
WO2014051398A1 (fr) | Composition pharmaceutique comprenant de l'acécaïnide ou un dérivé de celui-ci pour la prévention ou le traitement de maladies associées à une faiblesse musculaire | |
WO2022186658A1 (fr) | Composition pour la prévention, le soulagement ou le traitement de la sarcopénie, contenant du d-ribo-2-hexulose en tant que principe actif | |
WO2022071752A1 (fr) | Composition pour la prévention ou le traitement d'une maladie neuropsychologique, comprenant manf | |
WO2018135738A1 (fr) | COMPOSITION POUR INHIBER L'ACTIVITÉ DE LA MYOSTATINE, CONTENANT UNE PROTÉINE gla MATRICIELLE EN TANT QUE SUBSTANCE ACTIVE | |
WO2022071753A1 (fr) | Composition comprenant du plgf pour la prévention ou le traitement d'une maladie neuropsychologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16828049 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16828049 Country of ref document: EP Kind code of ref document: A1 |